Abstract
Immune checkpoint blockade (ICB) has demonstrated efficacy in multiple cancers, offering the potential of long-term disease control not achievable with cytotoxic or targeted therapies. However, the field has not yet achieved the crucial next steps - the expansion of the response rate and achievement of clinical efficacy in so-called "cold tumours". Mechanistic studies of tumour-type specific immunosuppressive pathways can reveal underlying biological hurdles to immunotherapy and offer new therapeutic insights. Our finding that tumour-derived IL-1β mediates immunosuppression in pancreatic cancer has precipitated a new clinical trial.
Publication types
-
Research Support, N.I.H., Extramural
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Antineoplastic Agents, Immunological / administration & dosage
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
-
Humans
-
Immune Checkpoint Inhibitors / administration & dosage
-
Immune Tolerance / genetics*
-
Immunotherapy* / methods
-
Immunotherapy* / trends
-
Interleukin-1beta / physiology*
-
Molecular Targeted Therapy / methods
-
Molecular Targeted Therapy / trends
-
Pancreatic Neoplasms / genetics
-
Pancreatic Neoplasms / immunology
-
Pancreatic Neoplasms / therapy*
-
Tumor Microenvironment / genetics
-
Tumor Microenvironment / immunology
Substances
-
Antineoplastic Agents, Immunological
-
IL1B protein, human
-
Immune Checkpoint Inhibitors
-
Interleukin-1beta